-
CAY10499: inhibitor of human hormone sensitive lipase
2026-09-16
A scenario-driven guide to using CAY10499 (SKU B7841) in lipid-metabolism, viability, proliferation, and cytotoxicity workflows. It connects biochemical potency, solvent handling, assay controls, and interpretation of immunometabolic studies to improve experimental reproducibility.
-
AM251: CB1 Receptor Antagonist Workflow
2026-09-16
AM251 is a high-potency pharmacological tool for testing whether neuronal, behavioral, metabolic, or cell-cycle effects depend on CB1 signaling. This workflow shows how to pair AM251 with pain, affective, obesity, and apoptosis assays while controlling for solvent, timing, and concentration-dependent off-target effects.
-
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-09-15
This Advanced Science study combines a macrophage phenotypic screen with TAM-avid nanodelivery to reduce SPP1 expression in tumor-associated myeloid cells. The lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions in several murine models, while also defining important limits for translation to human cancer biology.
-
Resiquimod (R-848) for Thermal Ablation Research
2026-09-15
Resiquimod (R-848) turns a thermal-ablation model into a coordinated chemo-immunology workflow by coupling TLR7/8 activation with localized delivery. This guide translates the MR@CaP@HA study into practical formulation, assay, control, and troubleshooting decisions for cancer immunotherapy research.
-
U0126-EtOH: Practical MEK1/2 Inhibitor Workflows
2026-09-14
U0126-EtOH enables pathway-focused interrogation of MEK1/2 and ERK signaling across neuronal, inflammatory, and leukemia models. This guide connects mechanism with executable workflows, assay controls, and troubleshooting strategies for more reproducible results.
-
S-Adenosylhomocysteine in Neural Differentiation Assays
2026-09-14
Use S-Adenosylhomocysteine to test whether methylation potential modifies radiation-associated neural differentiation rather than treating SAH as a nonspecific stressor. This workflow combines SAM/SAH ratio modulation with morphology, neuronal markers, and PI3K-STAT3-mGluR1 pathway analysis for a more discriminating assay.
-
Milk-Derived EV Uptake in Intestinal Stem Cell Models
2026-09-13
This study establishes porcine intestinal stem cell–based organoid models that more closely represent epithelial organization than conventional cell lines and uses them to examine milk-derived extracellular vesicle uptake. Its central finding is that uptake depends on epithelial orientation and intestinal region, while pharmacological endocytosis inhibition provides evidence that active internalization contributes to MEV entry.
-
CCK8 Workflow for Hydrogel Cancer Studies
2026-09-12
Use cck8 to connect targeted hydrogel design with quantitative cell viability measurement in breast cancer models. This practical workflow covers controls, dose–time experiments, particle interference, and interpretation of WST-8 readouts for reproducible cytotoxicity studies.
-
p-Cresyl Sulfate and Aortic Valve Calcification
2026-09-11
A 2026 study identifies p-Cresyl sulfate as an active enhancer of calcification in aortic valvular interstitial cells, rather than only a retained marker of kidney dysfunction. Its porcine-cell and rat CKD models connect PCS exposure with HIF-1α activation, klotho loss, and NF-κB/RUNX2 signaling, while testing klotho supplementation and SIRT1 activation as countermeasures.
-
GSK126: Mapping EZH2 Control of Immune Signaling
2026-09-11
Explore how GSK126, a selective EZH2 inhibitor, can connect H3K27me3 remodeling with chemokine expression and immune-cell recruitment. This article translates a decidual epigenetics study into a rigorous assay framework relevant to cancer epigenetics research and oncology drug development.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-10
Build a dual-readout workflow that separates mRNA uptake from productive translation using Cy5 fluorescence and Firefly luciferase bioluminescence. This guide combines practical transfection optimization with carrier-tropism insights from a lung-targeting mRNA study.
-
Tunicamycin for ER Stress Research
2026-09-10
Tunicamycin is a practical N-glycosylation inhibitor for building controlled ER-stress models, from RAW264.7 macrophage inflammation assays to glioblastoma resistance studies. This guide translates its mechanism into dose-finding, multi-readout workflows and troubleshooting strategies centered on GRP78, UPR signaling, COX-2, iNOS and FKBP9 biology.
-
AO/PI Staining Solution in Kidney Cell Models
2026-09-09
Learn how AO/PI Staining Solution supports fluorescence-based cell counting in diabetic nephropathy models. This guide connects membrane-integrity measurements with the inflammatory and apoptotic mechanisms reported for phillygenin, while clarifying what the assay can and cannot prove.
-
RNA Pol II Inhibition and the PDAR Mechanism
2026-09-09
Harper and colleagues show that RNA Pol II inhibition kills cells through an active apoptotic pathway triggered by depletion of hypophosphorylated Rpb1, rather than through transcriptional failure alone. The study defines the Pol II degradation-dependent apoptotic response and uses functional genomics to connect nuclear Pol II loss with mitochondrial cell death, providing a framework for interpreting the activity of transcription-targeting therapies.
-
TRIM66 and Monogenic Olfactory Receptor Expression
2026-09-08
The reference study identifies TRIM66 as an epigenetic repressor that helps convert initially polygenic olfactory receptor expression into the mature one-neuron–one-receptor state. Genetic loss of Trim66 disrupts receptor selection, neural activity, and innate olfactory behavior, linking enhancer repression to sensory-circuit function.